Clinical Trials Browser

Lomustine × 30 days × Clear all

NCT07100730 2026-04-16

IPAX BrIGHT

Phase 3 Recruiting

Brain Neoplasms, Glioblastoma, Neoplasm Recurrence, Local, Neoplasms, Central Nervous System Neoplasms

NCT04762069 2026-04-15

A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

Phase 2 Active not recruiting

Brain Neoplasms, Glioblastoma

NCT06325683 2026-04-15

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

Phase 2 Suspended

Glioblastoma

NCT06419946 2026-04-13

Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma

Phase 3 Recruiting

Glioblastoma

NCT03970447 2026-04-08

GBM AGILE

Phase 2/3 Recruiting

Glioblastoma, Recurrence

NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Phase 2 Active not recruiting

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT05095376 2026-04-03

Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

Phase 3 Active not recruiting

Glioblastoma, Gliosarcoma